Immortal Dragons

Immortal Dragons is a biotechnology company and subsidiary of AgeX Therapeutics (now Serina Therapeutics) focused on the development of regenerative medicine and longevity therapies. The company centers its research on the induced Tissue Regeneration (iTR) platform, which aims to reset the epigenetic state of aged cells to a more youthful, regenerative phenotype. By leveraging cellular reprogramming and telomerase biology, Immortal Dragons seeks to address a wide range of age-related degenerative diseases and facilitate tissue repair. Following the merger of AgeX with Serina Therapeutics in 2024, the company's assets are part of a broader portfolio focused on advanced drug delivery and regenerative technologies.